Sample 1Sample 2Sample 3 Phase III Clinical. Trial shall mean a clinical trial of aLicensed Productin human patients, which trial is designed (a)to establishthat the Licensed Product is safe and efficacious for itsintended use, (b) to define warnings, precautions andadverse reactionsthat areass...
内容提示: CPR-EFC5826-EN-E01 1/94 CLINICAL TRIAL PROTOCOL (Phase III trial) COMPOUND: SR141716 Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obese ...
including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor a...
In a randomized, placebo-controlled phase III clinical trial of dupilumab plus concomitant topical corticosteroids in children aged 6–11 years with severe AD, almost all children receiving dupilumab showed significant and clinically relevant improvements in AD skin signs, symptoms, and quality of life...
VEGA-3 is a randomized, double-masked, placebo-controlled, multi-center, Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% in 545 participants with presbyopia. Participants are randomized 3:2 to receive one drop of Phentolamine Ophthalmic Solution 0.75% or placebo each...
Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheime...
About KEYNOTE-671 KEYNOTE-671 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT03425643) evaluating neoadjuvant KEYTRUDA plus chemotherapy, followed by adjuvant KEYTRUDA as a single agent versus placebo plus neoadjuv...
today announced that it has been granted approval for a Phase III clinical trial (the "Trial") by the National Medical Products Administration (NMPA) inChinato explore the immunogenicity and safety of a simplified four-dose...
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small...
“For people living with ovarian cancer, there remains an unmet need for new treatment options that have the potential to improve outcomes,” said Dr.Gursel Aktan, vice president, global clinical development,Merck Research Laboratories. “KEYLYNK-001 is the first positive Phase 3 trial for KEYTRUD...